MRTX News and Press, Mirati Therapeutics Inc. From 01/06/20

Quick Take Black Diamond Therapeutics ( BDTX ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a platform that identifies small molecule kinase inhibitors, which help to slow or stop cancer. BDTX is a ...

Shares of Mirati Therapeutics (NASDAQ: MRTX) , a clinical-stage biopharmaceutical company, rose 27.9% in December, according to data from S&P Global Market Intelligence . Investors were revved up by results from an ovarian cancer study involving Mirati's sitravatinib plus tisle...

SAN DIEGO , Jan. 2, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13 th at 4:00 p.m. PST / 7:00 p.m. EST . Charle...

Merck ( MRK ) had announced that it would purchase ArQule ( ARQL ) for a total of $2.7 billion or $20 per share in cash. The main goal for this acquisition was that Merck could add a precision medicine oncology biotech to its portfolio. This acquisition should help the oncology portfol...

BeiGene (NASDAQ: BGNE ) and Mirati Therapeutics (NASDAQ: MRTX ) announces preliminary data from an ongoing Phase 1b trial of anti-PD-1 antibody tislelizumab in combination with tyrosine kinase inhibitor sitravatinib in patients with platinum-resistant ovarian cancer. More news on: BeiG...

CAMBRIDGE, Mass. and BEIJING, China, Dec. 13, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and...

How effective are the company's research and development efforts in relation to its size? - Philip Fisher Back on Oct. 24, 2017, Mirati Therapeutics ( MRTX ) exchanged hands at $5.20 when I first featured it in an expert interview . The stock continues its mega climb over the years. A...

Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...

SAN DIEGO , Nov. 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from its ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO ® ) in me...

Now is a great time to have biotech stocks in your portfolio. While biotech investing can be scary, because the small-cap companies are often unprofitable research-and-development labs, this is also where a lot of the cutting-edge science is happening. Let's see how Mirati Therapeutics (NA...